Multiple Myeloma Clinical Trials In Georgia

Trang chủ » Cc-92480-mm-003 » Multiple Myeloma Clinical Trials In Georgia

Có thể bạn quan tâm

Tell Us What You Think

In an effort to give you the best possible service, we would be grateful if you could take a few minutes of your time to answer a few questions.

  • About
  • Research
  • Education
  • Resources
  • Screening & Genetics
  • Find Cancer Care
  • Patient Navigation
  • Survivorship
  • Media & Events

Georgia's Online Cancer Information Center

HomeFind Cancer CareFind Clinical TrialsMultiple Myeloma back

Save Search Results

User Login

I'm a new user and need a user account

Email Password

Forgot your password?

Email Search Results

Your Name Your Email Recipient(s) Email Message Loading Close Multiple Myeloma Clinical Trials in Georgia **Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials. Cancer Type = Multiple Myeloma Cancer Type = Multiple Myeloma NCI ID Cancer Type Trial Name There are currently 60 active Multiple Myeloma clinical trials in Georgia. NCI ID Cancer Type Trial Name 1.
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT05675449 Protocol IDs C1071020NCI-2023-01590MAGNETISMM-20 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 2.
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05201781 Protocol IDs CR109123NCI-2022-013092020-005521-842023-505530-10-0068284528MMY4002 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 3.
A Phase 1 Multicenter, Open-Label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Combination with Alnuctamab, Mezigdomide, or Iberdomide in Participants with Relapsed and/or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT6163898 Protocol IDs Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 4.
A Phase 1b/2 Study of BGB-11417in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT04973605 Protocol IDs BGB-11417-105NCI-2022-072362021-003614-39U1111-1277-5444 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 5.
A Phase Ia/Ib Study of NMS-03597812 in Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia including patients with TP53 mutations
Cancer Type Leukemia, Multiple Myeloma NCT ID NCT06549790 Protocol IDs PERKA-812-003 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 6.
A Phase II Study of CAR T-ddBCMA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID 05396885 Protocol IDs 7.
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT06413498 Protocol IDs KT-US-679-0788NCI-2024-057122024-511188-26 Treatment Sites (2) City of Hope Atlanta Newnan Brian Wortz, PharmD, ACRP-CP 770-400-6169 Winship Cancer Institute of Emory University Atlanta 8.
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Cancer Type Multiple Myeloma NCT ID NCT06208150 Protocol IDs 64407564MMY3009NCI-2024-044242022-502446-27-0064407564MMY3009 Treatment Sites (1) City of Hope Atlanta Newnan Brian Wortz, PharmD, ACRP-CP 770-400-6169 9.
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT04910568 Protocol IDs GO42552NCI-2021-075432021-000238-33 10.
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT05651932 Protocol IDs KTX-MMSET-001NCI-2023-01697EUCTR No: 2022-500801-41-00 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 11.
A Study of Daratumumab
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05438043 Protocol IDs CR109200NCI-2024-004362021-006494-332022-500138-27-0054767414MMY3030 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 12.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT04133636 Protocol IDs CR1085812018-004124-1068284528MMY2003NCI-2019-07363 13.
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT04634552 Protocol IDs CR108920NCI-2021-021342017-002400-262023-504581-29-00TALMMY1001-PT3 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 14.
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05552222 Protocol IDs CR109237NCI-2022-111262022-000909-282023-503442-30-0064007957MMY3005 Treatment Sites (1) City of Hope Atlanta Newnan Brian Wortz, PharmD, ACRP-CP 770-400-6169 15.
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05827016 Protocol IDs IM048-022NCI-2023-065712022-501515-14U1111-1280-9492 Treatment Sites (3) Georgia Cancer Center at Augusta University Augusta University Cancer and Blood Center, LLC - Athens Medical Oncology Athens Winship Cancer Institute of Emory University Atlanta 16.
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
Cancer Type Multiple Myeloma NCT ID NCT06615479 Protocol IDs CA088-1007NCI-2025-00729 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 17.
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT06045806 Protocol IDs CA089-1043NCI-2024-012112022-501346-30U1111-1280-9736 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 18.
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05552976 Protocol IDs CA057-008NCI-2023-06472 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 19.
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type Multiple Myeloma NCT ID NCT05519085 Protocol IDs CA057-001NCI-2023-045572021-001957-302023-509859-13 Treatment Sites (1) University Cancer and Blood Center, LLC - Athens Medical Oncology Athens 20.
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT06121843 Protocol IDs CA088-1005NCI-2024-00171 Treatment Sites (2) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 Winship Cancer Institute of Emory University Atlanta 21. NCORP Trial
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Cancer Type Multiple Myeloma NCT ID NCT06271252 Protocol IDs OriCAR-017 US-P1NCI-2024-05382 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 22.
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Cancer Type Multiple Myeloma NCT ID NCT05137054 Protocol IDs R5458-ONC-2012NCI-2022-033732020-004638-39 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 23.
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
Cancer Type Multiple Myeloma NCT ID NCT06215118 Protocol IDs C1071030NCI-2024-03007MagnetisMM-30 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 24.
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT06106945 Protocol IDs D7230C00001NCI-2023-100342023-508590-89-00 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 25.
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05208307 Protocol IDs Winship5382-21NCI-2021-08385STUDY00003092 26. NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary NCT ID NCT04955808 Protocol IDs DCP-002DCP-002DCP-002NCI-2017-01572 27.
CAR T-cell Therapy in Patients With Renal Dysfunction ( Lymphodepleting Chemotherapy With Fludarabine and Cyclophosphamide Prior to Infusion of CAR T Cell Therapy in Patients With Moderate-Severe Renal Dysfunction)
Cancer Type Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma NCT ID NCT05909059 Protocol IDs NSH 1375 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 28. NCORP Trial
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Cancer Type Bladder Cancer, Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Esophogeal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Prostate Cancer , Sarcoma, Solid Tumor, Stomach/ Gastric Cancer, Thyroid Cancer NCT ID NCT05366881 Protocol IDs Adela-EDMRD-001NCI-2022-04272 Treatment Sites (1) Northeast Georgia Medical Center - Gainesville Gainesville Trena Davis 770-219-8822 29.
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Cancer Type Lymphoma, Multiple Myeloma, Plasma cell neoplasm NCT ID NCT06328699 Protocol IDs EU6011-23NCI-2023-09608STUDY00006456 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 30.
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT04352205 Protocol IDs WINSHIP4949-20NCI-2020-01133NCI-2020-01133 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 31.
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT03399799 Protocol IDs CR108404NCI-2018-0036764407564MMY10012017-002400-26 32.
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT05346835 Protocol IDs CR10896868284528MMY4006 ( Other Identifier ) (OTHER: Janss Treatment Sites (1) City of Hope Atlanta Newnan Brian Wortz, PharmD, ACRP-CP 770-400-6169 33. NCORP Trial
Financial Difficulty in Patients with Blood Cancer
Cancer Type Leukemia, Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05212233 Protocol IDs LCCC2063NCI-2022-10367 34.
Global Cardio Oncology Registry
Cancer Type Breast Cancer, Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm, Solid Tumor, Unknown Primary NCT ID NCT05598879 Protocol IDs IRB 22-211NCI-2024-07702 Treatment Sites (1) Georgia Cancer Center at Augusta University Augusta 35.
Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT04776395 Protocol IDs WINSHIP5157-20NCI-2020-08351 36.
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma
Cancer Type Bone Tumor, Multiple Myeloma, Plasma cell neoplasm NCT ID NCT03858205 Protocol IDs 16M-18-2NCI-2018-03600 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 37.
Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT04483206 Protocol IDs WINSHIP5001-20NCI-2020-04920STUDY00000449 38.
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Cancer Type Multiple Myeloma NCT ID NCT03732703 Protocol IDs MyDRUG (MMRC-085)NCI-2019-00698 Treatment Sites (1) Emory University Hospital - Atlanta Atlanta 39. NCORP Trial
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type Leukemia, Lung Cancer, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor NCT ID NCT04314401 Protocol IDs 1032310323NCI-2020-00750 Treatment Sites (18) Atlanta Cancer Care - Alpharetta Alpharetta Kristin Sieverding 770-777-1315 Atlanta Cancer Care - Conyers Conyers 404-303-3355 Atlanta Cancer Care - Cumming Cumming 404-303-3355 Atlanta Cancer Care - Decatur Decatur 404-303-3355 Atlanta Cancer Care - Stockbridge Jonesboro Andrena Jefferson 678 466-2069 Atlanta Cancer Care - Tower Atlanta 404-303-3355 Atlanta Gynecologic Oncology Atlanta Jen Cuvo 404-303-3355 Georgia Cancer Specialists - Athens Athens Cynthia Pirkle Georgia Cancer Specialists - Canton Canton Georgia Cancer Specialists - CenterPointe Sandy Springs Anila Lokhandwala 404-256-4777 ext 9242 Georgia Cancer Specialists - Decatur Decatur 404-303-3355 Georgia Cancer Specialists - Kennestone Marietta Greta Dudley Georgia Cancer Specialists - Macon-Coliseum Macon Sonia Hernandez 478-745-6130 x8152 Georgia Gynecologic Oncology Atlanta Jen Cuvo 404-303-3355 Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler Savannah Alaina Underberg 912-819-5778 Northside Hospital Cancer Institute Atlanta Northside Hospital Central Research Department 404-303-3355 University Gynecologic Oncology Atlanta Jen Cuvo 404-303-3355 40.
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type Multiple Myeloma NCT ID NCT04975997 Protocol IDs CC-220-MM-002NCI-2021-085182020-000431-49U1111-1260-2872 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 41.
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT04960579 Protocol IDs P-BCMA-ALLO1-001NCI-2022-02554 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 42.
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT03761108 Protocol IDs R5458-ONC-1826NCI-2019-029522018-003188-78 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 43.
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Cancer Type Kidney Cancer, Multiple Myeloma NCT ID NCT06142396 Protocol IDs 54767414MMY2095 Treatment Sites (1) Georgia Cancer Center at Augusta University Augusta 44.
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Cancer Type Multiple Myeloma NCT ID NCT04126200 Protocol IDs 208887NCI-2020-01127 45.
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Cancer Type Multiple Myeloma NCT ID NCT01838512 Protocol IDs CA204-008 Treatment Sites (2) Pearlman Cancer Center at South Georgia Medical Center Valdosta Jeffrey Hoy 229-259-4628 46. NCORP Trial
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Cancer Type Cancer-Related Syndrome, Hematopoietic Malignancies, Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Plasma cell neoplasm NCT ID NCT06665100 Protocol IDs PUL-042-207NCI-2024-09412CP120014 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 47.
Rifaximin in Treating Patients with Monoclonal Gammopathy
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT03820817 Protocol IDs Winship4480-18NCI-2018-02106IRB00106380 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 48.
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Cancer Type Breast Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Plasma cell neoplasm, Prostate Cancer NCT ID NCT06582017 Protocol IDs QXL138AM-001NCI-2024-07730 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 49.
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT06158841 Protocol IDs M22-574NCI-2024-034442023-506668-15-00 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 50. NCORP Trial
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Cancer Type Multiple Myeloma NCT ID NCT05396885 Protocol IDs ARC-112ANCI-2022-10407 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 51. NCORP Trial
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT06297226 Protocol IDs CA088-1000NCI-2024-02712 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 52.
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Cancer Type Leukemia, Multiple Myeloma NCT ID NCT05153330 Protocol IDs COVALENT-101NCI-2021-14401BF-MNN-101 Treatment Sites (1) Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT) Atlanta Caitlin Guzowski 404-851-8523 53.
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT04879043 Protocol IDs HDP-101-01NCI-2021-04304 54.
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Cancer Type Multiple Myeloma, Non-Hodgkin Lymphoma NCT ID NCT04756726 Protocol IDs CFT7455-1101NCI-2021-05587 55.
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Cancer Type Multiple Myeloma, Plasma cell neoplasm NCT ID NCT05317416 Protocol IDs C1071007NCI-2023-063502021-006052-14MagnetisMM-7 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 56. NCORP Trial
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type Multiple Myeloma, Non-Hodgkin Lymphoma, Plasma cell neoplasm NCT ID NCT02693535 Protocol IDs Pro00014171NCI-2017-00510 Treatment Sites (3) City of Hope Atlanta Newnan Brian Wortz, PharmD, ACRP-CP 770-400-6169 Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler Savannah Alaina Underberg 912-819-5778 Winship Cancer Institute of Emory University Atlanta 57. NCORP Trial
Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Cancer Type Multiple Myeloma NCT ID NCT03937635 Protocol IDs EAA173EAA173NCI-2018-02611 Treatment Sites (3) John B Amos Cancer Center Columbus Courtney Dean Alexander 706-780-6201 Pearlman Cancer Center at South Georgia Medical Center Valdosta Jeffrey Hoy 229-259-4628 Phoebe Cancer Center at Phoebe Putney Memorial Hospital Albany Dept of Clinical Research 229-312-5091 58.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm NCT ID NCT03805789 Protocol IDs CSL964_2001NCI-2019-033102018-000329-29 Treatment Sites (1) Emory University Hospital - Atlanta Atlanta 59.
Venetoclax and Tocilizumab for the treatment of Patients with Relapsed or Refractory t(11;14) Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT05391750 Protocol IDs WINSHIP5273-21NCI-2021-02510STUDY00002448 Treatment Sites (1) Winship Cancer Institute of Emory University Atlanta 60.
VitD3 Supplementation in Patients With Multiple Myeloma
Cancer Type Multiple Myeloma NCT ID NCT05846880 Protocol IDs GCC-22-044

Cancer Type

The location in the body in which cancer begins or the type of cell the cancer is made of.

Close

Protocol ID

Unique identifiers (letters & numbers) assigned to a protocol/clinical trial.

Close

NCT ID

National Clinical Trial ID (NCT ID) - unique identifier assigned to clinical trials once registered with clinicaltrials.org.

Close About Us Research Resources & Education Screening & Genetics Clinical Trials & Providers Cancer Navigators Survivorship Media, News & Events Contact Us Donate Take Our Survey Link to Us

Research

  • Investments in Research
  • Georgia NCORP

Screening & Genetics

  • Screening Guidelines for Common Cancers
  • Free Colon Cancer Screenings
  • Breast & Ovarian Cancer Screening Tool
  • Genetics & Cancer
  • Georgia Genetics Program
  • Breast Cancer License Plate Fund

Find Cancer Care

  • Find Clinical Trials
  • Find Cancer Doctors
  • Find Cancer Centers
  • Learn about new treatments being developed
  • Do you want help finding a clinical trial?
  • Efforts to expandclinical trials in Georgia

Survivorship

  • For Survivors
  • For Caregivers
  • For Healthcare Professionals
  • Survivors' Voices
  • Why Survivorship?
  • Survivorship Disparities

About Georgia CORE

  • Research
  • Education
  • Advocacy
  • Our Purpose
  • Our Leadership
  • Our Team

Education & Resources

  • Search Cancer Resources
  • Search Financial Assistance
  • Georgia Cancer Organizations
  • Georgia's Comprehensive Cancer Control Plan
  • National Guidelines
  • Publications, Presentations & Reports

Media, News & Events

  • Cancer & CORE News
  • Events & Conferences
  • Event Photo Library
  • Video Library
  • Newsletter Archive

Patient Navigation

  • Cancer Patient Navigators of Georgia
  • Search Patient Navigators
  • Clinical Trials Navigator Program
  • Member Login

Georgia CORE reduces the burden of cancer in our state through research, education, and advocacy.

Search

GO! Close Search

Từ khóa » Cc-92480-mm-003